Bio-Thera will obtain an upfront payment of $21m and could earn up to $143.5m in development and commercial milestones.

The FDA is set to review the Biologics License Applications (BLAs) for Alvotech’s AVT05, a proposed biosimilar to Simponi and Simponi Aria, branded forms of golimumab, which is a medication prescribed ...

The FDA accepted the biologics license applications (BLA) for AVT05, Alvotech’s and Teva Pharmaceuticals’ proposed biosimilar to golimumab (Simponi and Simponi Aria), which treats inflammatory ...

Alvotech’s proposed biosimilar to Simponi and Simponi Aria (golimumab), which are prescribed to treat a variety of inflammatory conditions. These are the first U.S. BLA filing acceptances announced ...

Simponi and Simponi Aria (golimumab) are prescribed to treat a variety of inflammatory conditions. Kroger is cutting about 200 employees across three office sites, and Albertsons is laying off ...

Credit: sergey kolesnikov/Shutterstock. Bio-Thera Solutions has signed an exclusive licence and commercialisation agreement with Intas Pharmaceuticals for the Simponi (golimumab) biosimilar, BAT2506 ...

Accord BioPharma Inc., the U.S. specialty division of Intas Pharmaceuticals Ltd., has reached an exclusive commercialization and license agreement with Bio-Thera Solutions for BAT2506, a biosimilar ...

Golimumab, a human monoclonal antibody, inhibits the biological activity of tumor necrosis factor alpha (TNF-alpha). Originator product Simponi ® is approved in the U.S. for moderate to severe ...

Simponi and Simponi Aria are also known as golimumab. The drugs, which are marketed by Johnson & Johnson (NYSE:JNJ), are used to treat rheumatoid arthritis, psoriatic arthritis and ankylosing ...